Abstract:Importance Cognitive impairment contributes significantly to clinical outcome and level of function in individuals with psychotic disorders. These impairments are present already at psychosis onset at a group level; however, the question of heterogeneity in cognitive function among patients has not been systematically investigated. Objective To provide an updated quantification of cognitive impairment at psychosis onset before patients receive potentially confounding antipsychotic treatment, and to investigate variability in cognitive function compared with healthy controls. Data Sources In this systematic review and meta-analysis, PubMed articles were searched up to September 15, 2022. Study Selection Original studies reporting data on cognitive function in antipsychotic drug–naive patients with first-episode psychosis (FEP) were included. Data Extraction and Synthesis Data were independently extracted by 2 researchers. Cognitive tasks were clustered according to 6 domains of the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery and the domain of executive function. Random-effects model meta-analyses of mean differences and coefficient of variation ratios (CVRs) were performed, as well as meta-regressions, assessment of study quality, and publication bias. Main Outcomes and Measures The main outcome measure was Hedges g for mean differences in cognition and CVR for within-group variability. Results Fifty studies were included in the analysis with a total of 2625 individuals with FEP (mean [SD] age, 25.2 [3.6] years, 60% male; 40% female) and 2917 healthy controls (mean [SD] age, 26.0 [4.6]; 55% male; 45% female). In all cognitive domains, the FEP group displayed significant impairment compared with controls (speed of processing: Hedges g = −1.16; 95% CI, −1.35 to −0.98; verbal learning: Hedges g = −1.08; 95% CI, −1.28 to −0.88; visual learning: Hedges g = −1.05; 95% CI, −1.27 to −0.82; working memory: Hedges g = −1.04; 95% CI, −1.35 to −0.73; attention: Hedges g = −1.03; 95% CI, −1.24 to −0.82; reasoning/problem solving: Hedges g = −0.90; 95% CI, −1.12 to −0.68; executive function: Hedges g = −0.88; 95% CI, −1.07 to −0.69). Individuals with FEP also exhibited a larger variability across all domains (CVR range, 1.34-1.92). Conclusions and Relevance Results of this systematic review and meta-analysis identified cognitive impairment in FEP before the initiation of antipsychotic treatment, with large effect sizes. The high variability within the FEP group suggests the need to identify those individuals with more severe cognitive problems who risk worse outcomes and could benefit the most from cognitive remediation.

Cognitive Function in First-Episode Adolescent-Onset Schizophrenia Before and after Treatment

Relationship Between Negative Symptoms and Neurocognitive Functions in Adolescent and Adult Patients with First-Episode Schizophrenia

The neurocognitive function in patients with first-episode schizophrenia treated in early stage

Epigenetic Clock Analysis of Blood Samples in Drug-Naive First-Episode Schizophrenia Patients.

Cognitive function changes with risperidone monotherapy and their relationship to psychotic symptoms in treatment-na?ve first-episode schizophrenia patients

Comparison of cognitive performance in first-episode drug-naïve schizophrenia, bipolar II disorder, and major depressive disorder patients after treatment

Short-term Effects of Antipsychotic Treatment on Cerebral Function in Drug-Naive First-Episode Schizophrenia Revealed by “resting State” Functional Magnetic Resonance Imaging

Study on the cognitive dysfunction in patients with first-episode schizophrenia

The comparative study of cognitive functions between familial and sporadic patients with first-episode schizophrenia

The Comparison of Impairment of Cognitive Function in First-Episode Schizophrenia, Bipolar Disorder and Major Depressive Disorder

Neurocognitive Effects of Atypical Antipsychotics in Patients with First-Episode Schizophrenia.

Impaired processing speed and attention in first-episode drug naive schizophrenia with deficit syndrome

Disrupted Intrinsic Functional Connectivity of the Cognitive Control Network Underlies Disease Severity and Executive Dysfunction in First-Episode, Treatment-Naive Adolescent Depression.

Neurocognitive deficits in first-episode schizophrenic patients and their first-degree relatives

Cognitive function in patients with first-episode schizophrenia and individuals at high-risk for psychosis

Cognitive Impairments in First-Episode Drug-Naive and Chronic Medicated Schizophrenia: MATRICS Consensus Cognitive Battery in a Chinese Han Population.

Study of Executive Function in Adolescent Patients with First-Episode Schizophrenia

Cognitive Function and Variability in Antipsychotic Drug–Naive Patients With First-Episode Psychosis

Abnormal global-brain functional connectivity and its relationship with cognitive deficits in drug-naive first-episode adolescent-onset schizophrenia

Relationship Between Iq and Memory and Executive Function in First Episode Schizophrenia

Cognitive function and treatment response trajectories in first-episode schizophrenia: evidence from a prospective cohort study